Quarter Period Consolidated Statement Of Comprehensive Income

KYORIN Pharmaceutical Co., Ltd. - Filing #7330327

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
Quarter period consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
52,995,000,000 JPY
5,322,000,000 JPY
52,995,000,000 JPY
52,995,000,000 JPY
52,995,000,000 JPY
3,005,000,000 JPY
3,005,000,000 JPY
3,005,000,000 JPY
3,005,000,000 JPY
4,723,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
201,000,000 JPY
-578,000,000 JPY
Foreign currency translation adjustment
-340,000,000 JPY
229,000,000 JPY
Remeasurements of defined benefit plans, net of tax
2,736,000,000 JPY
-394,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
30,000,000 JPY
5,000,000 JPY
Other comprehensive income
2,627,000,000 JPY
-737,000,000 JPY
Comprehensive income
7,949,000,000 JPY
3,986,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
7,949,000,000 JPY
3,986,000,000 JPY
Comprehensive income attributable to non-controlling interests
JPY
JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.